ArticlePloS one2019

EGFR mutations and AKT phosphorylation are markers for sensitivity to combined MCL-1 and BCL-2/xL inhibition in non-small cell lung cancer.

Shawn J Rice et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.